Trial details
AGIOS A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of AG-881 in Subjects with Residual or Recurrent Grade 2 Glioma with an IDH1 or IDH2 Mutation
To find out more about this trial and your cancer treatment options, please speak with your doctor.
Trial short name: AGIOS
Official title: AGIOS A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of AG-881 in Subjects with Residual or Recurrent Grade 2 Glioma with an IDH1 or IDH2 Mutation
Principal Investigator: Dr. James Perry
Cancer type: Central Nervous System
Cancer location: Brain
Disease stage: Early Cancer
Trial phase: Phase 3
Intervention: Medication - AG-881
Registration #:
NCT04164901 
Trial description:
The purpose of this study is to look at the effectiveness of AG-881 in patients with brain tumours. Patients with residual or recurrent Grade 2 oligodendroglioma or astrocytoma with an IDH1 or IDH2 mutation who have undergone surgery and who meet additional criteria may be eligible to participate. Participants will be randomized to receive either AG-881 or placebo. It is a blinded study where the patient, doctor and study staff will not know which group a patient is in.
Please ask physician.
